The Role of ADCs in Different Subgroups

Panelists discuss how:
antibody-drug conjugates (ADCs) have emerged as a cornerstone in HER2-targeted therapy, offering enhanced precision by linking potent cytotoxics to HER2 antibodies. The experts discuss strategies to maximize benefit while mitigating toxicity, focusing on patient selection, dose adjustments, and long-term management. They evaluate the expanding role of ADCs in HER2-low disease and their potential integration into early-stage treatment settings. The session highlights how ADCs bridge the gap between efficacy and tolerability, offering better quality-of-life outcomes and redefining treatment sequencing.